Hepatic Adducts, Circulating Antibodies, and Cytokine Polymorphisms in Patients with Diclofenac Hepatotoxicity

Hepatology

Volumn 39, Issue 5, 2004, Pages 1430-1440

  Aithal, Guruprasad P ^a,d   Ramsay, Lesley ^b   Daly, Ann K ^a   Sonchit, Nhareet ^b   Leathart, Julian B S ^a   Alexander, Graeme ^c   Kenna, J Gerald ^b,e   Caldwell, John ^b,f   Day, Christopher P ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d QUEEN S MEDICAL CENTRE   (United Kingdom)

^e University of Liverpool ^*  (United Kingdom)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTISERUM; CYTOKINE; DICLOFENAC; DNA; DRUG METABOLITE; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; LIVER PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN RECOGNITION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOBLOTTING; IMMUNOSTIMULATION; LIVER; LIVER TOXICITY; MALE; MULTIPLE DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; RAT; SERUM; TH2 CELL;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES; DICLOFENAC; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEPATITIS, TOXIC; HUMANS; INTERLEUKIN-10; INTERLEUKIN-4; LIVER; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROTEINS; RECEPTORS, INTERLEUKIN-4;

EID: 2342541211     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20205     Document Type: Article

References (39)

1. Rodriguez LAG, Williams F, Derby LE, Dean AD, Jick H. Acute liver injury associated with non-steroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med 1994;154:311-316.
2. Banks AT, Zimmerman HJ, Ishak KG, Harter JG. Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. HEPATOLOGY 1995;22:820-827.
3. Scully LJ, Clarke D, Barr RJ. Diclofenac-induced hepatitis in 3 cases with features of autoimmune chronic active hepatitis. Dig Dis Sci 1993;8:744-751.
4. Boelsterli UA, Zimmerman HJ, Kretz-Rommel A. idiosyncratic liver toxicity of non-steroidal anti-inflammatory drugs: molecular mechanisms and pathology. Crit Rev Toxicol 1995;25:207-235.
5. Beaune P, Pessayre D, Dansette PM, Mansuy D, Manns M. Autoantibodies against cytochrome P450: role in human diseases. Adv Pharmacol 1994;30:199-245.
6. Pumford NR, Myers TG, Davila JC, Highet RJ, Pohl LR. Immunochemical detection of liver protein adducts of the non-steroidal anti-inflammatory drug diclofenac. Chem Res Toxicol 1993:6;147-150.
7. Kretz-Rommel A, Boelsterli UA. Didofenac covalent protein binding is dependent on acyl glucuronide formation and is inversely related to P450-mediated acute cell injury in cultured rat hepatocytes. Toxicol Appl Pharmacol 1993;120:155-161.
8. Kretz-Rommel A, Boelsterli UA. Selective protein adducts to membrane proteins in cultured rat hepatocytes exposed to diclofenac: radiochemical and immunochemical analysis. Mol Pharmacol 1994;45:237-244.
9. Hargus SJ, Amouzedeh HR, Pumford NR, Myers TG, McCoy SC, Pohl LR. Metabolic activation and immunochemical localisation of liver protein adducts of the non-steroidal anti-inflammatory drug diclofenac. Chem Res Toxicol 1994;7:575-582.
10. Wade LT, Kenna JG, Caldwell J. Immunochemical detection of mouse hepatic protein adducts derived from the non-steroidal anti-inflammatory drugs diclofenac, sulindac and ibuprofen. Chem Res Toxicol 1997;10:546-555.
11. Kretz-Rommel A, Boelsterli UA. Cytotoxic activity of T cells and non-T cells from diclofenac-immunised mice against cultured syngeneic hepatocytes exposed to didofenac. HEPATOLOGY 1995;22:213-222.
12. Bougie D, Johnson ST, Weitekamp LA, Aster RH. Sensitivity to a metabolite of diclofenac as a cause of acute immune haemolytic anaemia. Blood 1997;90:407-413.
13. Aithal GP, Day CP, Leathart J, Daly AK. Relationship of polymorphism in CYP2C9 to genetic susceptibility to didofenac-induced hepatitis. Pharmacogenetics 2000;10:511-518.
14. de Waal Malefyt R, Yssel H, Rocarolo M-G, Spits H, de Vries JE. Interleukin 10. Curr Opin Immunol 1992;4:314-322.
15. Louis H, Van Laetherm JL, Wu W, Quertinmont E, Degraef C, Berg KV, et al. Interleukin-10 controls neutrophilic infiltration, hepatocyte proliferation, and liver fibrosis induced by carbon tetrachloride in mice. HEPATOLOGY 1998;28:1607-1615.
16. Nelson DR, Lauwers GY, Lau JYN, Davis GL. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology 2000;118:655-660.
17. Eskdale J, Kube D, Tesch H, Gallagher G. Mapping of the IL-10 gene and further characterisation of the 5′ flanking sequence. Immunogenetics 1997;46:120-128.
18. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997;24:1-8.
19. Grove J, Daly AK, Bassendine MF, Gilvarry E, Day CP. Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut 2000;46:540-545.
20. Lazarus M, Hajeer AH, Turner D, Sinnott P, Worthington J, Olliet WE, et al. Genetic variation in the interleukin 10 gene promoter and systemic lupus erythematosus. J Rheumatol 1997;24:2314-2317.
21. Lim S, Crawley E, Woo P, Barnes PJ. Haplotype associated with low interleukin-10 production in patients with severe asthma. Lancet 1998;152:113.
22. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;383:787-793.
23. Rosenwasser LJ, Klemm DJ, Dreback JK, Inamma H, Masca JJ, Klinnert M, et al. Promoter polymorphism in the chromosome 5 gene duster in asthma and atopy. Clin Exp Allergy 1995;25(Suppl 2):74-78.
24. Kawashima T, Noguchi E, Arinami T, Kobayahi KY, Nakagawa H, Otsuka F, et al. Linkage and association of an interleukin 4 gene polymorphism with atopic dermatitis in Japanese families. J Med Genet 1998;35:229-239.
25. Noguchi E, Shibasaki M, Arinami T, Takeda K, Yokouchi Y, Kiwashima T, et al. Association of asthma and interleukin-4 promoter gene in Japanese. Clin Exp Allergy 1998;28:449-453.
26. Cantagrel A, Navaux F, Loubet-Lescoulie P, Nourhashemi F, Enault G, Abbal M, et al. Interleukin-1b, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms: relationship to occurrence and severity of rheumatoid arthritis. Arthritis Rheum 1999;42:1093-1100.
27. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE. The IL-4 receptor: signaling mechanisms and biologic functions. Ann Rev Immunol 1999;17:701-738.
28. Shirakawa I, Deichmann KA, Izubara I, Mao I, Adra CN, Hopkin JM. Atopy and asthma: genetic variants of IL-4 and IL-13 signalling. Immunol Today 2000;21:60-64.
29. Hershey GK, Fredrich MF, Esswein LA, Thomas ML, Chatila TA. The association of atopy with a gain of function mutation in the alpha subunit of the interleukin-4 receptor. N Engl J Med 1997;337:1720-1725.
30. Benichou C. Criteria of drug-induced liver disorders. Report of an International Consensus Meeting. J Hepatol 1990;11:272-276.
31. Aithal PG, Day CP. The natural history of histologically proven drug-induced liver disease. Gut 1999;44:731-735.
32. Gardener I, Bergin P, Stening P, Kenna JG, Caldwell J. Immunochemical detection of covalently modified protein adducts in livers of rats treated with methyleuginol. Chem Res Toxicol 1996;9:713-721.
33. Daly AK, Steen VM, Fairbrother KS, Idle JR. CYP2D6 multialleism. Methods Enzymol 1996;272:199-210.
34. Aithal GP, Day CP, Leathart JBS, Daly AK, Hudson M. Association of single nucleotide polymorphism in the interleukin-4 and interleukin-4 receptor gene with Crohn's disease in a British population. Genes and Immunity 2001;2:44 -47.
35. Pessayre D. Role of reactive metabolites in drug-induced hepatitis. J Hepatol 1995;23(Suppl 1):16-24.
36. Pessayre D, Larrey D, Biour M. Drug-induced liver injury. In: Bircher J, Benhamou JP, McIntyre N, Rizzetto M, Rodes J, eds. Oxford Textbook of Clinical Hepatology. Volume II. Oxford: Oxford University Press, 1999: 1261-1315.
37. Package insert. Voltaren (didofenac sodium). Ardsley, New York: Geigy Pharmaceuticals of Ciba-Geigy Corporation, October 1988.
38. Bourdi M, Masubuchi Y, Reilly TP, Amouzadeh HR, Martin JL, George JW, et al. Protection against acemminophcn-induced liver injury and lethality by interleukin 10: role of inducible nitric oxide synthase. HEPATOLOGY 2002;35:289-298
39. Berson A, Freneaux E, Larrey D, Lepage V, Douay C, Mallet C, et al. Possible role of HLA in hepatotoxicity. An exploratory study in 71 patients with drug-induced idiosyncratic hepatitis. J Hepatol 1994;20:336-42.